Joseph Keegan Net Worth

Joseph Keegan biography

Dr. Joseph D. Keegan Ph.D. serves as Independent Director of the Company. Dr. Joseph Keegan currently serves as a director and advisor for Interpace Diagnostics as well as a number of privately held life science companies. From 2007 until its sale to Pall Corporation in 2012, Dr. Keegan served as President and Chief Executive Officer of ForteBio, Inc. Dr. Keegan joined ForteBio from Molecular Devices Corporation, where he served as President and Chief Executive Officer from 1998 to 2007. Prior to Molecular Devices, Dr. Keegan held leadership positions at Becton Dickinson, Leica, Inc. and GE Medical Systems. He has also served on numerous public and private company boards of life science tools companies, including as Chair of Fluidic Analytics and Executive Chair of Halo Labs. Dr. Keegan holds a Ph.D. in Physical Chemistry from Stanford University.

What is the salary of Joseph Keegan?

As the Independent Director of Bio-Techne Corp, the total compensation of Joseph Keegan at Bio-Techne Corp is 273,759$. There are 15 executives at Bio-Techne Corp getting paid more, with Charles Kummeth having the highest compensation of 11,483,800$.

How old is Joseph Keegan?

Joseph Keegan is 67, he's been the Independent Director of Bio-Techne Corp since 2017. There are 2 older and 17 younger executives at Bio-Techne Corp. The oldest executive at Bio-Techne Corp is Roeland Nusse, 70, who is the Independent Director.

What's Joseph Keegan's mailing address?

Joseph's mailing address filed with the SEC is 614, Northeast McKinley Place, Minneapolis, Hennepin County, Minnesota, 55413, United States.

Insiders trading at Bio-Techne Corp

Over the last 21 years, insiders at Bio-Techne Corp have traded over 37,160,097$ worth of Bio-Techne Corp stock and bought 4,361 units worth 454,370$ . The most active insiders traders include Charles R. Kummeth、Rupert Vessey、John L Higgins. On average, Bio-Techne Corp executives and independent directors trade stock every 23 days with the average trade being worth of 964,850$. The most recent stock trade was executed by Kim Kelderman on 29 August 2024, trading 1,492 units of TECH stock currently worth 99,919$.

What does Bio-Techne Corp do?

bio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide.

Bio-Techne Corp executives and stock owners

Bio-Techne Corp executives and other stock owners filed with the SEC include:

• Charles Kummeth,
  President, Chief Executive Officer, Director
• Charles R. Kummeth,
  CEO, Pres & Director
• James Hippel,
  Chief Financial Officer, Executive Vice President - Finance
• David Eansor,
  President - Protein Sciences
• Kim Kelderman,
  President - Diagnostics and Genomics
• Brenda Furlow,
  Senior Vice President, General Counsel, Corporate Secretary
• James T. Hippel,
  Exec. VP of Fin. & CFO
• Norman David Eansor,
  Pres of Protein Sciences Segment
• Kim Kelderman,
  Pres of Diagnostics & Genomics
• Brenda S. Furlow J.D.,
  Exec. VP, Gen. Counsel, Sec. & Chief Compliance Officer
• Robert Baumgartner,
  Independent Chairman of the Board
• Rupert Vessey,
  Independent Director
• John Higgins,
  Independent Director
• Randolph Steer,
  Independent Director
• Roeland Nusse,
  Independent Director
• Alpna Seth,
  Independent Director
• Joseph Keegan,
  Independent Director
• David Clair,
  IR Contact Officer
• Julie Bushman,
  Independent Director
• Kevin Smyth,
  Sr. VP & Chief Digital Officer
• Luca Cicchetti,
  Managing Director
• Brenda Everson,
  Sr. VP of HR
• Kevin S. Gould,
  Sr. VP of Diagnostics Reagents Division
• Struan Robertson,
  VP of HR
• Robert M. Gavin,
  VP of Corp. Devel.
• Gerry Andros,
  VP of Sales and Marketing
• Karen A Holbrook,
  Director
• Roger C Lucas,
  
• Charles A Dinarello,
  
• J. Fernando Bazan,
  Chief Technical Officer
• Robert M. Gavin,
  Sen. VP Protein Platforms
• Kevin S Gould,
  SVP Clinical Controls
• Kevin J Reagan,
  Senior VP Biotech
• Gregory J Melsen,
  VP Finance and CFO
• Thomas E Oland,
  President
• Howard V Oconnell,
  Director
• Marcel Veronneau,
  Vice Pres-Hematology Oper.
• James A Weatherbee,
  Chief Scientific Officers
• Monica Tsang,
  Vice President of Research
• Christopher S Henney,
  Director
• G A Herbert,
  Director
• Harold J Wiens,
  
• William Geist,
  PRESIDENT, PROTEIN SCIENCES
• Shane Bohnen,
  SVP - General Counsel
• Matthew Mc Manus,
  President - DGS
• Judith V Klimovsky,
  Director